Reviva’s advisory board consists of highly successful, experienced and qualified professionals associated with Pharmaceutical and medical industries.

Henry Nasrallah, MD

IMG_11032015_205815Dr. Henry Nasrallah is professor and chairman of the Department of Neurology and Psychiatry at Saint Louis University, and holds the Sydney W. Souers Endowed Chair. He is a widely recognized neuropsychiatrist, educator and researcher. Following his psychiatric residency at the University of Rochester and neuroscience fellowship at the NIH, he served as chair of the Ohio State University Department of Psychiatry for twelve years. In January 2003, he joined the University of Cincinnati College of Medicine as Associate Dean and Professor of Psychiatry and Neuroscience. In October 2013, he joined St. Louis University to chair the integrated Department of Neurology and Psychiatry.

Dr. Nasrallah’s research focuses on the neurobiology and psychopharmacology of schizophrenia and related psychoses. He has published 380 scientific articles, 440 abstracts, as well as 11 books. He is Editor-In-Chief of two journals (SCHIZOPHRENIA RESEARCH and CURRENT PSYCHIATRY) and is the co-founder of the Schizophrenia International Research Society (SIRS). He is board certified in in adult psychiatry. He is a fellow in the American College of Neurpsychopharmacology (ACNP) a distinguished fellow of the American Psychiatric Association (APA), and has served as president of the Cincinnati Psychiatric Society and as president of the American Academy of Clinical Psychiatrists. He has twice received the NAMI Exemplary Psychiatrist Award and was chosen as the U.S.A. Teacher of the Year by the Psychiatric Times. He has received over 90 research grants and is listed in all editions of the book “Best Doctors in America”.

Herbert Y. Meltzer, MD

IMG_11032015_205815Herbert Y Meltzer, MD, is Professor of Psychiatry and Behavioral Sciences and Professor of Pharmacology and Physiology at the Feinberg School of Medicine Chicago, Il. and visiting Professor at the Soochow University School of Medicine in Suzhou, China. He received his BA with Distinction from Cornell University, an MA in Chemistry from Harvard, and his MD from Yale University and has been President of the American College of Neuropsychopharmacology (ACNP) and the Collegium International Neuro-psychopharmacologicum (CINP). He served as editor of Psychopharmacology: The Third Generation of Progress and co-editor of the ACNP journal, Neuropsychopharmacology, and is a member of the editorial board of numerous scientific journals.

Dr. Meltzer is the recipient of the Efron and Paul Hoch Awards of the ACNP, the Noyes Prize of the Commonwealth of Pennsylvania, the Edward J. Sachar Award from Columbia University, the Lieber Prize for Schizophrenia Research from NARSAD, the Stanley Dean Award for Research in Schizophrenia of the American College of Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Earl Sutherland Prize for Achievement in Research of Vanderbilt University (2004), the Research Prize of the American Psychiatric Association (2005), and the Grant Liddle Award for Clinical Research from Vanderbilt University (2008), and the Lifetime Achievement Award of the Winter Conference on Psychosis Research (2011). He has chaired the Young Investigator Grant Review Committee for the Brain and Behavior Research Foundation (formerly NARSAD) since its inception and the International Psychopharmacology Algorithm Project, a web-based algorithm to guide the treatment of schizophrenia ( Hirsch index is 106.

Dr. Meltzer’s research interests include the discovery, development, and optimal utilization of clozapine and other novel pharmacologic treatments for schizophrenia and related disorders, including bipolar disorder, the causes and novel treatments for cognitive impairment in schizophrenia and bipolar disorder, the elucidation of the mechanism of action of antipsychotic and other psychotropic drugs, especially the role of 5-HT2A and 5-HT1A receptors, the development of genetic biomarkers for personalized medicine in psychiatry, and the causes and prevention of suicide.

John M. Kane, MD

IMG_11032015_205815John M. Kane, MD is Vice President for Behavioral Health Services of the North Shore – Long Island Jewish Health System and Chairman of Psychiatry at The Zucker Hillside Hospital. He is Chairman of Psychiatry and Professor of Psychiatry and Molecular Medicine at the Hofstra North Shore-LIJ School of Medicine. Dr. Kane received his B.A. from Cornell University and his M.D. from the New York University School of Medicine. He currently directs the NIMH-funded Advanced Center for Interventions and Services Research in Schizophrenia at The Zucker Hillside Hospital. He has been a member of the Board of Scientific Counselors for NIMH, and he has served on the council of the American College of Neuropsychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration.

Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations’ Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.